{"id":56139,"date":"2025-06-16T11:39:09","date_gmt":"2025-06-16T09:39:09","guid":{"rendered":"https:\/\/marimon-abogados.com\/?p=56139"},"modified":"2025-06-16T11:39:26","modified_gmt":"2025-06-16T09:39:26","slug":"the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025","status":"publish","type":"post","link":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/","title":{"rendered":"The Pharmaceutical Sector and Competition: Developments in Europe and Spain (2024 \u2013 Q1 2025)"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Over the past year, both European and Spanish competition authorities have intensified their scrutiny of business practices within the pharmaceutical sector. Below is a summary of the key decisions issued by the European Commission and the CNMC (Spanish National Markets and Competition Commission), along with the most relevant regulatory developments.<\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>1. Europe: EU Competition Law and the Pharmaceutical Sector<\/strong><\/h5>\n\n\n\n<h6 class=\"wp-block-heading\">Denigration Practices and Abuse of Dominant Position<\/h6>\n\n\n\n<p class=\"wp-block-paragraph\">The European Commission has addressed several anticompetitive practices, with particular focus on denigration campaigns carried out by undertakings holding a dominant position. Noteworthy cases include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Vifor Pharma (Case AT.40577)<\/strong>: a campaign targeting Monofer (Pharmacosmos), based on the dissemination of misleading information. Although the infringement was confirmed, the Commission did not impose a fine, having accepted a package of commitments following a confidential settlement.<\/li>\n\n\n\n<li><strong>Teva Copaxone (Case AT.40588)<\/strong>: the Commission imposed a fine of \u20ac462.6 million for abuse of the patent system and for conducting a denigration campaign against Synthon GA.<\/li>\n<\/ul>\n\n\n\n<h6 class=\"wp-block-heading\">SNBB Cartel<\/h6>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Case AT.40636<\/strong>: sanctions were imposed on six pharmaceutical undertakings for price-fixing and market-sharing arrangements involving the active ingredient SNBB, which is essential in the manufacture of Buscopan.<\/li>\n<\/ul>\n\n\n\n<h6 class=\"wp-block-heading\">Ongoing Investigation: Zoetis<\/h6>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Case AT.40734<\/strong>: potential abuse of dominance under investigation following the discontinuation of the drug Ranevetmab, acquired through the purchase of Nexvet Biopharma.<\/li>\n<\/ul>\n\n\n\n<h6 class=\"wp-block-heading\">Category Management Practices: Belgium<\/h6>\n\n\n\n<p class=\"wp-block-paragraph\">Fines were imposed on Johnson &amp; Johnson Consumer, Boehringer Ingelheim, and Haleon for anticompetitive conduct in the category management of OTC medicines, involving restrictive planogram practices.<\/p>\n\n\n\n<h6 class=\"wp-block-heading\">Merger Control \u2013 Authorised Transactions<\/h6>\n\n\n\n<p class=\"wp-block-paragraph\">In 2024 and Q1 2025, the European Commission cleared seven concentrations in the sector, including:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Novo Holdings \/ Novo Nordisk \/ Catalent<\/li>\n\n\n\n<li>Carlyle \/ Vantive<\/li>\n\n\n\n<li>KKR \/ Impilo \/ Immedica<\/li>\n\n\n\n<li>CD&amp;R \/ Opella Healthcare SAS<\/li>\n\n\n\n<li>Roquette \/ IFF Pharma Solutions<\/li>\n\n\n\n<li>Carlyle \/ SK Capital \/ Bluebird<\/li>\n<\/ul>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>2. Spain: CNMC Resolutions<\/strong><\/h5>\n\n\n\n<h6 class=\"wp-block-heading\">Closed Proceedings<\/h6>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>IMQ<\/strong>: no indications of abuse of dominance were found and the case was closed.<\/li>\n\n\n\n<li><strong>General Council of Dentists<\/strong>: case dismissed due to lack of sufficient evidence concerning restrictions on patients\u2019 choice of dental prosthetics.<\/li>\n<\/ul>\n\n\n\n<h6 class=\"wp-block-heading\">Ongoing Sanctioning Proceedings<\/h6>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CGCOF and several Provincial Pharmaceutical Colleges (Case S\/0009\/23)<\/strong>: under investigation for allegedly recommending the use of specific digital applications to the detriment of competitors.<\/li>\n\n\n\n<li><strong>Sandoz, Bexal and Bluetab (Case S\/0014\/23)<\/strong>: suspected exchange of sensitive commercial information regarding generic medicine orders.<\/li>\n\n\n\n<li><strong>Sanitas \u2013 Generali (Case S\/0008\/25)<\/strong>: possible coordination of pricing and commercial terms of insurance policies.<\/li>\n\n\n\n<li><strong>HEFAME<\/strong>: failure to comply with commitments made in a previous merger clearance.<\/li>\n<\/ul>\n\n\n\n<h6 class=\"wp-block-heading\">Approved Concentrations<\/h6>\n\n\n\n<p class=\"wp-block-paragraph\">Notable transactions authorised include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Haiyingkang \/ SRAAS<\/li>\n\n\n\n<li>Rovi \/ Insud \/ Innverte \/ Terafront JV<\/li>\n\n\n\n<li>Miura \/ Healthtech HTBA<\/li>\n\n\n\n<li>Esteve \/ Takeda<\/li>\n\n\n\n<li>Eurofins \/ Synlab<\/li>\n\n\n\n<li>Bidco \/ Stamina Topco<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">One transaction (<strong>MCH \/ CASP \/ Druni \/ Arenal<\/strong>) was cleared subject to structural and behavioural commitments. Another (<strong>Curium \/ IRAB<\/strong>) is under Phase II review, as the transaction would result in a combined market share exceeding 60% in a key market.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h5 class=\"wp-block-heading\"><strong>3. New Pharmaceutical Regulation in Spain<\/strong><\/h5>\n\n\n\n<h6 class=\"wp-block-heading\">2024\u20132028 Strategy and Draft Medicines and Medical Devices Bill<\/h6>\n\n\n\n<p class=\"wp-block-paragraph\">In December 2024, the Spanish Government presented its <strong>Pharmaceutical Industry Strategy 2024\u20132028<\/strong>. In April 2025, it published the draft <strong>Medicines and Medical Devices Act<\/strong>, which introduces reforms such as:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A <strong>new pricing system<\/strong>: combining selected price models and reference pricing schemes.<\/li>\n\n\n\n<li><strong>Active ingredient-based prescribing<\/strong>: including new rules for pharmacy-level substitution based on patient preference and price thresholds.<\/li>\n<\/ul>\n\n\n\n<h6 class=\"wp-block-heading\">CNMC\u2019s Position<\/h6>\n\n\n\n<p class=\"wp-block-paragraph\">Since its 2022 market study, the CNMC has advocated for a more flexible framework allowing price differentiation to encourage competition. Its recommendations include:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Allowing alternative medicines to be offered at the point of dispensing.<\/li>\n\n\n\n<li>Reforming reference pricing to avoid automatic price equalisation.<\/li>\n\n\n\n<li>Expanding the sets of medicines subject to reference pricing.<\/li>\n<\/ul>\n\n\n\n<h6 class=\"wp-block-heading\">Industry Reaction<\/h6>\n\n\n\n<p class=\"wp-block-paragraph\">Five major pharmaceutical associations have raised concerns about the potential impact of the proposed reforms on innovation and international competitiveness. However, the legislative text remains at draft stage and is subject to parliamentary review and potential amendment.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Over the past year, both European and Spanish competition authorities have intensified their scrutiny of business practices within the pharmaceutical sector. Below is a summary of the key decisions issued by the European Commission and the CNMC (Spanish National Markets and Competition Commission), along with the most relevant regulatory developments. 1. Europe: EU Competition Law &#8230; <a title=\"The Pharmaceutical Sector and Competition: Developments in Europe and Spain (2024 \u2013 Q1 2025)\" class=\"read-more\" href=\"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/\" aria-label=\"Read more about The Pharmaceutical Sector and Competition: Developments in Europe and Spain (2024 \u2013 Q1 2025)\">Read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_thinkrank_schema_form_data":"","_thinkrank_selected_schema_type":"","_thinkrank_additional_schemas":"","_thinkrank_canonical_url":"","_thinkrank_og_title":"","_thinkrank_og_description":"","_thinkrank_og_image":"","_thinkrank_twitter_title":"","_thinkrank_twitter_description":"","_thinkrank_twitter_image":"","_thinkrank_imported_from":"","_thinkrank_focus_keywords":[],"_thinkrank_focus_keyword":"","_thinkrank_robots_meta_enabled":0,"_thinkrank_robots_meta":"","_thinkrank_advanced_robots_meta":"","_thinkrank_exclude_from_search":0,"_thinkrank_exclude_from_archives":0,"_thinkrank_primary_category":0,"footnotes":""},"categories":[338],"tags":[],"class_list":["post-56139","post","type-post","status-publish","format-standard","hentry","category-articulo-en"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Competition in Pharma: Key Developments 2024\u20132025<\/title>\n<meta name=\"description\" content=\"Key EU and Spanish competition law cases in the pharma sector, including denigration, cartel conduct and upcoming regulatory reforms.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Competition in Pharma: Key Developments 2024\u20132025\" \/>\n<meta property=\"og:description\" content=\"Key EU and Spanish competition law cases in the pharma sector, including denigration, cartel conduct and upcoming regulatory reforms.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/\" \/>\n<meta property=\"og:site_name\" content=\"Marim\u00f3n Abogados\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-16T09:39:09+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-16T09:39:26+00:00\" \/>\n<meta name=\"author\" content=\"MarinaGfez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"MarinaGfez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/\"},\"author\":{\"name\":\"MarinaGfez\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#\\\/schema\\\/person\\\/7a373e8849fb601cb56929977c730501\"},\"headline\":\"The Pharmaceutical Sector and Competition: Developments in Europe and Spain (2024 \u2013 Q1 2025)\",\"datePublished\":\"2025-06-16T09:39:09+00:00\",\"dateModified\":\"2025-06-16T09:39:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/\"},\"wordCount\":617,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#organization\"},\"articleSection\":[\"Articles\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/\",\"url\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/\",\"name\":\"Competition in Pharma: Key Developments 2024\u20132025\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#website\"},\"datePublished\":\"2025-06-16T09:39:09+00:00\",\"dateModified\":\"2025-06-16T09:39:26+00:00\",\"description\":\"Key EU and Spanish competition law cases in the pharma sector, including denigration, cartel conduct and upcoming regulatory reforms.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/marimon-abogados.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The Pharmaceutical Sector and Competition: Developments in Europe and Spain (2024 \u2013 Q1 2025)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#website\",\"url\":\"https:\\\/\\\/marimon-abogados.com\\\/\",\"name\":\"Marim\u00f3n Abogados\",\"description\":\"M\u00e1s de 90 A\u00f1os prestando asesoramiento jur\u00eddico\",\"publisher\":{\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/marimon-abogados.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#organization\",\"name\":\"Marim\u00f3n Abogados\",\"url\":\"https:\\\/\\\/marimon-abogados.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/marimon-abogados.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/marimon-logo.svg\",\"contentUrl\":\"https:\\\/\\\/marimon-abogados.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/marimon-logo.svg\",\"width\":259,\"height\":59,\"caption\":\"Marim\u00f3n Abogados\"},\"image\":{\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/marimon-abogados.com\\\/#\\\/schema\\\/person\\\/7a373e8849fb601cb56929977c730501\",\"name\":\"MarinaGfez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8507afa38b3fb3fbb3f7249641dd5b9600cf8dcbbe86a4ce6c56bce9b20c26f7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8507afa38b3fb3fbb3f7249641dd5b9600cf8dcbbe86a4ce6c56bce9b20c26f7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/8507afa38b3fb3fbb3f7249641dd5b9600cf8dcbbe86a4ce6c56bce9b20c26f7?s=96&d=mm&r=g\",\"caption\":\"MarinaGfez\"},\"url\":\"https:\\\/\\\/marimon-abogados.com\\\/en\\\/author\\\/marina\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Competition in Pharma: Key Developments 2024\u20132025","description":"Key EU and Spanish competition law cases in the pharma sector, including denigration, cartel conduct and upcoming regulatory reforms.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/","og_locale":"en_US","og_type":"article","og_title":"Competition in Pharma: Key Developments 2024\u20132025","og_description":"Key EU and Spanish competition law cases in the pharma sector, including denigration, cartel conduct and upcoming regulatory reforms.","og_url":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/","og_site_name":"Marim\u00f3n Abogados","article_published_time":"2025-06-16T09:39:09+00:00","article_modified_time":"2025-06-16T09:39:26+00:00","author":"MarinaGfez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"MarinaGfez","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/#article","isPartOf":{"@id":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/"},"author":{"name":"MarinaGfez","@id":"https:\/\/marimon-abogados.com\/#\/schema\/person\/7a373e8849fb601cb56929977c730501"},"headline":"The Pharmaceutical Sector and Competition: Developments in Europe and Spain (2024 \u2013 Q1 2025)","datePublished":"2025-06-16T09:39:09+00:00","dateModified":"2025-06-16T09:39:26+00:00","mainEntityOfPage":{"@id":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/"},"wordCount":617,"commentCount":0,"publisher":{"@id":"https:\/\/marimon-abogados.com\/#organization"},"articleSection":["Articles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/","url":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/","name":"Competition in Pharma: Key Developments 2024\u20132025","isPartOf":{"@id":"https:\/\/marimon-abogados.com\/#website"},"datePublished":"2025-06-16T09:39:09+00:00","dateModified":"2025-06-16T09:39:26+00:00","description":"Key EU and Spanish competition law cases in the pharma sector, including denigration, cartel conduct and upcoming regulatory reforms.","breadcrumb":{"@id":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/marimon-abogados.com\/en\/the-pharmaceutical-sector-and-competition-developments-in-europe-and-spain-2024-q1-2025\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/marimon-abogados.com\/"},{"@type":"ListItem","position":2,"name":"The Pharmaceutical Sector and Competition: Developments in Europe and Spain (2024 \u2013 Q1 2025)"}]},{"@type":"WebSite","@id":"https:\/\/marimon-abogados.com\/#website","url":"https:\/\/marimon-abogados.com\/","name":"Marim\u00f3n Abogados","description":"M\u00e1s de 90 A\u00f1os prestando asesoramiento jur\u00eddico","publisher":{"@id":"https:\/\/marimon-abogados.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/marimon-abogados.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/marimon-abogados.com\/#organization","name":"Marim\u00f3n Abogados","url":"https:\/\/marimon-abogados.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/marimon-abogados.com\/#\/schema\/logo\/image\/","url":"https:\/\/marimon-abogados.com\/wp-content\/uploads\/2023\/08\/marimon-logo.svg","contentUrl":"https:\/\/marimon-abogados.com\/wp-content\/uploads\/2023\/08\/marimon-logo.svg","width":259,"height":59,"caption":"Marim\u00f3n Abogados"},"image":{"@id":"https:\/\/marimon-abogados.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/marimon-abogados.com\/#\/schema\/person\/7a373e8849fb601cb56929977c730501","name":"MarinaGfez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/8507afa38b3fb3fbb3f7249641dd5b9600cf8dcbbe86a4ce6c56bce9b20c26f7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/8507afa38b3fb3fbb3f7249641dd5b9600cf8dcbbe86a4ce6c56bce9b20c26f7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8507afa38b3fb3fbb3f7249641dd5b9600cf8dcbbe86a4ce6c56bce9b20c26f7?s=96&d=mm&r=g","caption":"MarinaGfez"},"url":"https:\/\/marimon-abogados.com\/en\/author\/marina\/"}]}},"_links":{"self":[{"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/posts\/56139","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/comments?post=56139"}],"version-history":[{"count":0,"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/posts\/56139\/revisions"}],"wp:attachment":[{"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/media?parent=56139"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/categories?post=56139"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/marimon-abogados.com\/en\/wp-json\/wp\/v2\/tags?post=56139"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}